Previous 10 | Next 10 |
IPFsym will enable new software and services revenue by aiding development of IPF therapies Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has r...
The following slide deck was published by Simulations Plus, Inc. in conjunction with this event. For further details see: Simulations Plus (SLP) Presents At 16th Annual Virtual Technology & Media Virtual Conference - Slideshow
Drug Discovery has historically been the most expensive and lengthy step in creating new drugs. SDGR's physics-based software cuts the time in half as well as the costs. Along with being a software company with 80% GMs, 99% customer retention rate and robust growth, they have their pr...
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will participate in Craig-Hallum’s 18 th Annua...
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 16 th Annual Needham Virtual Tech...
Simulations Plus (SLP) announced that it has been approved for trading on The Nasdaq, effective May 13 market open; it will continue trading under the same symbol."The growth investments we've made over the past few years have led to accelerated financial performance and increased the gl...
Industry-driven enhancements further establish ADMET Predictor® as the preferred platform for discovery PBPK simulations Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, an...
Simulations Plus (SLP) has announced that its DILIsym Services division has renewed licenses to its DILIsym® software platform, for use by the U.S. FDA.The renewal ensures continued DILIsym software access to FDA employees across all FDA divisions at the FDA’s discretion...
FDA Renewal Allows for Evaluation of DILIsym Submissions by Sponsors Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) divi...
Simulations Plus's total return overperformed the Dow average for my 64 month test period by 471.60%, which is fantastic. Simulations Plus three-year past CAGR of 19% is well above average and will give you great growth with the increasing need for testing new drugs faster than before...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...